In a paper published in PLoS Medicine, representatives of regulatory agencies in the U.K., France, and the Netherlands argue that clinical trial data should not be considered commercial confidential information. While adequate protection of privacy for study subjects is important, excessive protection does not serve the common good or, in fact, the intent of their participation. Full clinical trial reports should be made available to enable independent re-analysis of drugs’ benefits and risks, they argue.
Related Items:
How drug companies continue to hide the true story of Tamiflu and other drugs from the American public
Drug Data Shouldn’t Be Secret
Neuraminidase inhibitors—the story behind the Cochrane Review
More on the need for data sharing — the Tamiflu example
Drug Data Shouldn’t Be Secret
